Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

BACKGROUND: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T7...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Ichihara, Eiki, Hotta, Katsuyuki, Kubo, Toshio, Higashionna, Tsukasa, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://ncbi.nlm.nih.gov/pubmed/30034635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25705
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky